Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT04811040 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Oral Lenacapavir
DRUG: Subcutaneous Lenacapavir
DRUG: Teropavimab
DRUG: Zinlirvimab

Sponsor

Gilead Sciences